National Biotechnology Safety Act
- Bill Number
- S. 2697
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-03: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-09-22T12:15:49Z
AI-Generated Summary
National Biotechnology Safety Act (S. 2697)
Purpose
The legislation aims to promote the safe development and use of biotechnology by authorizing the National Science Foundation (NSF) to fund research on potential risks to the environment, human health, and animal health from biotech products. It also directs NSF to commission an independent study by the National Academies of Sciences, Engineering, and Medicine to evaluate biotech safety and benefits, ultimately helping federal regulators create clearer guidelines for biotech oversight.
Key Provisions
- Research Program Establishment (Section 3):
- NSF's Director must create a funding program within its Directorate for Technology, Innovation, and Partnerships to support research on risks from releasing biotech-modified organisms (e.g., genetically altered plants, animals, or microbes) into the environment.
- Funding can be awarded through grants, cooperative agreements, or temporary research groups to eligible recipients, including universities, nonprofit organizations, industry partners, federally funded research centers, and consortia.
- Award decisions prioritize projects based on commercialization potential, current knowledge gaps, alignment with research priorities, and ethical, legal, and social considerations.
- Research priorities include:
- Identifying unintended genetic changes or effects from biotech methods.
- Developing ways to manage and minimize risks in research, farming, and product use.
- Monitoring how biotech organisms spread or persist, including advanced tools like gene drives (mechanisms that spread genetic changes through populations).
- Studying gene transfer between biotech and natural organisms.
- Comparing biotech impacts to traditional breeding methods or other human activities.
- Assessing risks from combining biotech with emerging technologies like artificial intelligence.
- NSF can set performance metrics (e.g., goals and deadlines) for projects and coordinate with agencies like the U.S. Department of Agriculture (USDA), Food and Drug Administration (FDA), and Environmental Protection Agency (EPA) for regulatory input and oversight.
- Funding: $50 million authorized annually from fiscal year 2026 through 2030, with flexibility to use additional NSF resources.
- National Academies Study (Section 4):
- NSF, in consultation with USDA, FDA, EPA, and other relevant agencies, must contract with the National Academies within 90 days of enactment for a two-phase study on biotech safety and benefits.
- Phase One (completed within 1 year): Compares risks of biotech genetic modification tools to traditional methods; recommends risk-based assessment frameworks; identifies needed research on tool safety.
- Phase Two (completed within 2 years): Evaluates safety and benefits of existing commercial biotech products versus traditional ones; recommends ways to assess future products; suggests processes to reduce unnecessary regulation for low-risk biotech items; identifies further research needs.
- Reports from each phase must be submitted to NSF, consulting agencies, and relevant congressional committees (Senate Commerce, Science, and Transportation; House Science, Space, and Technology) within 90 days of completion, and made publicly available online.
- Within 180 days after both reports, NSF must submit to Congress a plan for federal research to address any identified gaps in biotech safety knowledge.
- Funding: $1.5 million authorized for fiscal year 2026.
Significant Changes to Existing Law
This bill introduces new authorities for NSF by creating a dedicated research program and mandating a comprehensive National Academies study, which did not previously exist in this form. It builds on existing NSF funding mechanisms but specifies biotech risk assessment as a priority, without directly amending prior laws like those governing USDA, FDA, or EPA regulations. The emphasis on coordination could lead to more integrated federal approaches to biotech oversight.
Potential Impacts
- Government Agencies: Enhances NSF's role in biotech research while requiring collaboration with regulatory bodies (e.g., USDA, FDA, EPA), potentially streamlining approvals for safe products and informing policy updates. The implementation plan could guide future federal budgets and programs.
- Citizens: Improves public safety by addressing health and environmental risks from biotech, such as in food, medicine, or agriculture, potentially leading to better-managed innovations that benefit health and farming without undue hazards.
- International Relations: Minimal direct impact, but U.S.-led research on global issues like gene drives or environmental monitoring could influence international standards for biotech trade and safety, positioning the U.S. as a leader in evidence-based regulation.
- Broader effects include faster commercialization of low-risk biotech products, reducing regulatory burdens while prioritizing high-risk areas.
Main Stakeholders Affected
- Federal Agencies: NSF (lead), USDA, FDA, EPA, and other expert bodies for research funding, coordination, and regulatory application.
- Research and Academic Institutions: Universities, nonprofits, and federally funded centers as primary recipients of grants.
- Industry and Private Sector: Biotech companies, agricultural firms, and innovators benefiting from risk assessments that aid product development and market entry.
- Public and Civil Society: Citizens, environmental groups, and ethicists influenced by safer biotech applications and studies addressing social implications.
- Congress: Oversight committees receiving reports and plans to shape future legislation.
Notable Legal, Constitutional, or Political Implications
- Legal: Promotes "risk-proportionate" regulation, potentially allowing lighter oversight for low-risk biotech products compared to traditional ones, which could challenge or refine existing statutes like the Coordinated Framework for the Regulation of Biotechnology (1986). Includes ethical and social reviews in funding criteria, ensuring broader accountability.
- Constitutional: Aligns with Congress's powers to fund science and promote general welfare (Article I, Section 8), without raising significant federalism issues, though state governments are noted in findings as potential beneficiaries of informed policies.
- Political: Bipartisan introduction (by Sens. Young and Padilla) signals cross-aisle support for balancing innovation and safety amid growing biotech use in defense, agriculture, and health. The public reporting requirement enhances transparency, but funding levels may spark debates on federal spending priorities. No overt controversies, but emphasis on convergence with AI could preempt future tech-policy tensions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-09-03: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-09-03: Introduced in Senate
Bill Versions
- National Biotechnology Safety Act — issued 2025-09-03 — PDF (10 pages)